Drug Development

Chemokine Receptor Antagonists Move to Phase II Trials

Published in AIDS Weekly, August 7th, 2000

Research from Belgium shows that chemokine receptor antagonists are promising anti-HIV agents.

"The chemokine receptors CXCR4 and CCR5 are used as coreceptors by the T-tropic X4 and M-tropic R5 HIV-1 strains, respectively, for entering their target cells," reported E. De Clercq from the Rega Institute for Medical Research, Belgium. "Viral entry can be blocked by the natural ligands for CXCR4 (SDF-1(alpha)) and CCR5 (RANTES, MIP-1(alpha), MIP-1(beta), and derivatives thereof).

"Among the chemokines, LD78(beta), an isoform of MIP-1(alpha) (LD78(alpha)), has proved particularly effective in suppressing CCR5-using R5 HIV-1 replication."

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2000-08-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry